logo

6505--Radiopharmaceuticals Pluvicto / Lutathera - Nuclear Med, Ind

The scope, dates and status of this tender. A free account opens every field.

Source: SAM.gov

Tender
Special Notice

Notice of Intent to Sole Source Requirement The Department of Veterans Affairs, VA Healthcare System, Network 10 Contracting Office intends to negotiate a sole source contract for a FDA approved radioactive therapy drug under the authority of GSAR 538.7104-3(b)(1)(ii): Only one source is capable of providing the supplies or services required at the level of quality required because the supplies or

Status
Closed
Sector
Nuclear, Residential, Manufacturing (Industrial), Road, Commercial
Location
United States of America
Updated
3 Nov 2026
Source
SAM.gov

ConstructChat

Ask ConstructChat about 6505--Radiopharmaceuticals Pluvicto / Lutathera - Nuclear Med, Ind

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Tender Information FAQ

Tender Information

3 Q
The tender “6505--Radiopharmaceuticals Pluvicto / Lutathera - Nuclear Med, Ind” is a tender record in Taiyo, linked to the Nuclear sector. It is issued for works, goods, or services related to United States of America.

Participants

Not available for this record.

Status

Original status

special notice

Taiyo status

Closed

Taiyo last update

2026-11-03

Contact

Not available for this record.

Description

Description

Notice of Intent to Sole Source Requirement The Department of Veterans Affairs, VA Healthcare System, Network 10 Contracting Office intends to negotiate a sole source contract for a FDA approved radioactive therapy drug under the authority of GSAR 538.7104-3(b)(1)(ii): Only one source is capable of providing the supplies or services required at the level of quality required because the supplies or services are unique or highly specialized. The associated NAICS code for this is 325412. The vendor will be Novartis, Route 10, East Hanover, NJ, 07936. Description of services: SUPPLY: This is a new FDA approved radioactive therapy drug. The therapeutic effectiveness of this radioactive drug has changed standard patient care guidelines and now patients diagnosed with prostate cancer are recommended to have Lu177 PLUVICTO as a treatment option. Also needed is the purchase of the Lu177 LUTATHERA. A One Year firm fixed price contract shall be awarded. It is the Government's belief that only the proposed candidate possesses the required capabilities to successfully meet this requirement. It is the Government's intention to solicit and negotiate with only this source. This notice of intent is not a request for competitive proposals. It is not a solicitation or request for offers.

Original sector

Not Identified

Location

Country

United States of America (USA)

Source

Source

SAM.gov

URL

More Details

Record type

Tender

Sector

Nuclear, Residential, Manufacturing (Industrial), Road, Commercial

Article published date

2026-01-30

More on this tender

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this tender
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this tender